NIH R43 funding opportunities: Small Business Innovation Research (SBIR) Phase I
2 NIH notices for R43 (Small Business Innovation Research (SBIR) Phase I) are open and 2 forecast. A small business tests the feasibility of a technology or...
- Open notices2
- Forecast2
- Projects funded under them9,272
Open NIH R43 notices
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
Open - Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
Open
Forecast R43 notices
- NIEHS Worker Training Program’s SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
Forecast - Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)
Forecast
Institutes that fund R43 projects under these notices
| Institute or center | Projects |
|---|---|
| National Cancer Institute (NCI) | 1,306 |
| National Heart Lung and Blood Institute (NHLBI) | 1,063 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 949 |
| National Institute on Aging (NIA) | 778 |
| National Institute of General Medical Sciences (NIGMS) | 754 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 699 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 571 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 389 |
| National Institute on Drug Abuse (NIDA) | 388 |
| National Institute of Mental Health (NIMH) | 365 |
Closed R43 notices
- RFA-DA-25-048: Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
- PAR-23-311: NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
- RFA-MD-24-006: Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)
- PAR-24-131: Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed)
- PAR-24-132: Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required)
- PAS-22-196: Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)
- PAR-23-032: Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)
- PA-24-247: PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- PA-24-248: PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
- PA-24-246: PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
- PA-24-245: PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- RFA-NS-23-006: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
- PAR-23-213: Interactive Digital Media (IDM) Biomedical Science Resources for Pre-College Students and Teachers (SBIR) (R43/R44 Clinical Trial Not Allowed)
- PAR-25-308: Small Business Informatics Tools for the Pangenome (R43 Clinical Trial Not Allowed)
- RFA-DA-26-016: Medical Devices for Pediatric Population Affected by Substance Use and Addiction (R43 - Clinical Trials Optional)
- PAR-24-158: Addressing Health Inequities in Clinical Diagnostics (R43/R44 Clinical Trials Not Allowed)
- RFA-DA-26-018: Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional)
- RFA-DA-23-021: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
- PA-25-212: Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed)
- PAR-21-225: Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R43/R44 Clinical Trial Not Allowed)
- RFA-DA-25-050: Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44 - Clinical Trial Optional)
- PAR-24-263: SBIR Solutions to Enable Population Genomic Screening (R43/R44 Clinical Trial Optional)
- PA-21-345: Administrative Supplements to Promote Diversity in Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed)
- RFA-ES-24-003: SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
- RFA-DA-25-054: Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)
- PA-21-268: Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- PAR-24-106: Solutions to Enable Regional Genomic Medicine eConsult Services (R43/R44 Clinical Trial Optional)
- RFA-AA-24-001: High-Throughput Screening (HTS) Platform for Discovery of Medications to Treat Alcohol Use Disorder (R43/R44 Clinical Trials Not Allowed)
- PA-23-231: PHS 2023-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
- PA-23-230: PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- RFA-DA-25-052: Tools for decentralized clinical trials for substance use disorder (R43/R44 Clinical Trials Optional)
- PAR-22-073: Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed)
- PAR-21-297: Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R43/R44 Clinical Trial Not Allowed)
- PAR-21-266: NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
- RFA-DA-24-018: Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R43/R44 Clinical Trial Optional)
- RFA-AG-24-042: NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R43/R44 Clinical Trial Optional)
- RFA-MD-23-003: Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)
- RFA-ES-23-005: SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
- RFA-ES-23-008: Novel Approaches for Developmental Neurotoxicity Testing (R43/R44 Clinical Trial Not Allowed)
- PAR-21-247: Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial not allowed)
- PA-22-177: PHS 2022-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
- PA-22-178: PHS 2022-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- PA-22-176: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- RFA-AG-23-029: NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R43/R44 Clinical Trial Optional)
- RFA-HG-21-008: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44)
- RFA-DA-23-017: Therapeutic Development of Psychoplastogenic Compounds for Substance Use Disorders (R43/R44 - Clinical Trials Not Allowed)
- RFA-DA-23-020: Novel Drug (DDT) and Medical Device Development Tools (MDDT) to Help Expedite Creation and Regulatory Approvals of New Therapies for Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
- RFA-ES-22-006: New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed)
- RFA-DK-21-011: Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed)
- RFA-DK-21-012: Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)
- RFA-DK-21-021: Support for Small Business Innovation Research (SBIR) to Develop New Methods and Technologies for Assessment of Risk and for Early Diagnosis and Prognosis of Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)
- RFA-ES-22-004: SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
- PA-21-259: PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- PA-21-262: PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- PA-21-260: PHS 2021-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
- RFA-MD-22-004: Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)
- RFA-DA-22-023: Advancing Validated Drug Targets for Substance Use Disorders (R43/R44 - Clinical Trial Not Allowed)
- RFA-ES-21-008: Innovative Approaches for Improving Environmental Health Literacy (R43/R44 Clinical Trial Not Allowed)
- RFA-AG-22-007: NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R43/R44 Clinical Trial Optional)
- RFA-DA-22-001: Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction (R43/R44 Clinical Trial Optional)
- RFA-DA-22-019: Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R43/R44 - Clinical Trial Not Allowed)
- RFA-ES-21-005: SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
- RFA-HD-22-019: User-Based Design to Aid in Contraceptive Development by Small Business (R43 Clinical Trial Not Allowed)
- RFA-HD-22-010: Technologies to Advance Precision Medicine for Reproductive Health and Infertility (R43, R44 Clinical Trial Optional)
- RFA-HD-22-018: Biomarker Research to Support Fertility Regulation Development by Small Business (R43 Clinical Trial Optional)
- RFA-MD-21-006: Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)
Questions people ask
What is an NIH R43?
R43 is NIH's activity code for the Small Business Innovation Research (SBIR) Phase I. A small business tests the feasibility of a technology or product. Each notice sets its own budget limit, project length and due dates.
How many NIH R43 funding opportunities are open?
2 notices are open on Grants.gov, and 2 more are forecast, as of the latest data.